Back to Search Start Over

Treatment Updates in Antineutrophil Cytoplasmic Autoantibodies (ANCA) Vasculitis.

Authors :
Jain K
Jawa P
Derebail VK
Falk RJ
Source :
Kidney360 [Kidney360] 2021 Apr; Vol. 2 (4), pp. 763-770. Date of Electronic Publication: 2021 Apr 29.
Publication Year :
2021

Abstract

ANCA vasculitis is a small-vessel vasculitis (SVV) resulting in inflammation of small- and medium-sized blood vessels. Since the initial description of SVV, there have been tremendous advances in our understanding of its pathogenesis. Over the last decade, we have made significant progress in understanding the pathogenesis and improving the treatment and prognosis of patients with ANCA vasculitis. Patient and renal survival has improved, and treatment is moving toward individualizing care, minimizing severe adverse events, and preventing relapse. This review focuses on treatment updates in ANCA vasculitis, duration of therapy, and management of relapses. We also describe the existing treatment protocols used at our institution.

Details

Language :
English
ISSN :
2641-7650
Volume :
2
Issue :
4
Database :
MEDLINE
Journal :
Kidney360
Publication Type :
Academic Journal
Accession number :
34095854
Full Text :
https://doi.org/10.34067/KID.0007142020